1. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts;Bhatt;N Engl J Med,2023
2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04053634 Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations (RESOLUTE), 2019. Available from: http://clinicaltrials.gov/ct/show/NCT04053634?order=1 [updated 22.8.23].
3. Benralizumab for the Prevention of COPD Exacerbations;Criner;N Engl J Med,2019
4. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT04133909. Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE), 2019. Available from: http://clinicaltrials.gov/ct/show/NCT04133909?order=1 [updated 28.8.23].
5. Mepolizumab for eosinophilic Chronic Obstructive Pulmunory Disease;Pavord;NEJM,2017